Bridging studies

Area of Science:

• Vaccinology
• Clinical Trials
• Immunology

Background:

• Large-scale vaccine efficacy trials are resource-intensive.
• Generalizing vaccine efficacy to new populations often requires additional studies.
• Bridging studies offer a potential method to avoid duplicative efficacy trials.

Purpose of the Study:

• To explore the utility of bridging studies in vaccine development.
• To define the role of immunogenicity data in extrapolating vaccine efficacy.
• To identify factors influencing vaccine efficacy and the decision to conduct bridging studies.

Main Methods:

• Reviewing previous experiences with vaccine bridging studies.
• Analyzing the correlation between immune response and vaccine-induced immunity.
• Assessing ethnic and vaccine-related factors impacting vaccine efficacy.
• Defining bridging studies as trials to demonstrate equivalent immunogenicity.

Main Results:

• Bridging studies can avoid the need for large-scale efficacy trials in new populations.
• Immunogenicity data can be used to extrapolate efficacy when a correlate of protection exists.
• The absence of a correlate of protection makes the bridging process more complex.
• Identifying factors influencing efficacy is critical for deciding on bridging studies.

Conclusions:

• Bridging studies are essential for demonstrating equivalent immunogenicity across populations.
• Careful consideration of influencing factors is necessary for successful vaccine efficacy extrapolation.
• Bridging studies streamline vaccine development by leveraging existing efficacy data.